Abraxis BioScience Bolsters Manufacturing and Global Operational Expertise With Key Senior Executives.LOS ANGELES Los Angeles (lôs ăn`jələs, lŏs, ăn`jəlēz'), city (1990 pop. 3,485,398), seat of Los Angeles co., S Calif.; inc. 1850. -- Abraxis BioScience, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ABBI Advanced Breast Biopsy Instrument (ABBI) Uses a rotating circular knife and thin heated electrical wire to remove a large cylinder of abnormal breast tissue. Mentioned in: Fibrocystic Condition of the Breast ), an integrated, global biopharmaceutical company, today appointed three executives to its manufacturing and operational senior management ranks: Frank Harmon as executive vice president, global operations Global Operations is a first-person shooter computer game developed by Barking Dog Studios and published by both Crave Entertainment and Electronic Arts. It was released in March of 2002, following its public multiplayer beta version which contained only the Quebec map. ; Sam Trippie as senior vice president, manufacturing; and Jeff Silverman as vice president, operations integration and new technology development. "Bolstering our manufacturing operations Manufacturing operations concern the operation of a facility, as opposed to maintenance, supply and distribution, health, and safety, emergency response, human resources, security, information technology and other infrastructural support organizations. and global operational expertise has been of paramount importance and we are thrilled to add and promote senior executives with such a high caliber of experience and expertise," said Patrick Soon-Shiong, M.D., chairman and chief executive officer of Abraxis BioScience. Harmon, joins Abraxis as executive vice president, global operations. In his role, Harmon will be responsible for overseeing the Global Manufacturing Operations as well as the Corporate Quality Assurance and Quality Control and the Supply Chain Organizations. Harmon has approximately 30 years' experience within the pharmaceutical industry. Prior to joining Abraxis, he was the senior vice president, manufacturing operations for the Sterile Technologies Group at Cardinal Health where he was responsible for multiple sites throughout the United States and Puerto Rico. He has also served as vice president, biopharmaceutical operations for Aventis Behring. Harmon earned an MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from St. Louis University and undergraduate B.S. degrees in Biology and Chemistry from Western Kentucky University Student Body Profile WKU had a total enrollment in the Fall Semester of 2002 (the latest published figures) of 17,818 students. Out of this total, 73% were full-time and 85% were undergraduates. Ethnic and racial minority enrollment was just under 13% at 2,097. . Trippie, is being promoted to the position of senior vice president, manufacturing at Abraxis and will report to Harmon. In his role, Trippie will be responsible for the manufacturing operations in Chicago, Illinois; Grand Island, New York Grand Island is a town and an island in Erie County, New York, USA. As of the 2000 census, the town population was 18,621. The current town name derives from the French name "La Grande Isle," as Grand Island is the largest island in the Niagara River. ; Barceloneta, Puerto Rico Barceloneta is a municipality in Puerto Rico and is located in the north region, bordering the Atlantic Ocean, north of Florida, east of Arecibo and west of Manati. Barceloneta is spread over 3 wards and Barceloneta Pueblo (The downtown area and the administrative center of the ; and Barbengo, Switzerland, as well as the SAP product material specifications, corporate engineering and packaging development. Mr. Trippie joined the company in 1998 as vice president of manufacturing. He had previously served as vice president of manufacturing at Fujisawa USA, Inc., a pharmaceutical company. Prior to that, Mr. Trippie was vice president of manufacturing at Sanofi and held various positions in quality assurance and manufacturing at Baxter International. Trippie holds a B.S. in Microbiology from the University of Southwest Louisiana. Silverman, joins Abraxis as vice president, operations integration and new technology development and will report to Harmon. In his role, Silverman will be responsible for technical support and product/process transfer as well as the evaluation of potential business opportunities to leverage Abraxis' broad and proprietary manufacturing capabilities. His deep experience at biologically based manufacturing companies such as Alpha Therapeutics, Cancervax and Cell Genesys provides a strong platform for the Abraxis biosimilar initiatives. Silverman most recently served as vice president, manufacturing operations for CancerVax Corp., a biotechnology company focused on the development of cell based cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine . Prior to that, he served a similar role with Cell Genesys, Inc., with responsibility for technology transfer and production of oncolytic viruses and gene therapy products. Silverman spent several years with MannKind Corp. where he was focused on building the capital and technical infrastructure to develop and commercialize novel biologic solutions in the areas of allergy and diabetes. He held a number of management positions in the 20 years he spent at Alpha Therapeutics, primarily in the areas of Production Management, Engineering, and Technical Services. Silverman holds a B.S. in Biochemistry from California State University, Los Angeles California State University, Los Angeles (also known as Cal State L.A., CSULA, or "'CSLA"') is a public university, part of the California State University system. , and an MBA from the Drucker School of Management at Claremont Graduate University Claremont Graduate University (formerly The Claremont Graduate School) was founded in 1925 in the city of Claremont, California. It is one of two graduate institutions in the prestigious Claremont Colleges consortium, the other being the Keck Graduate Institute. . About Abraxis BioScience, Inc. Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast cancer. Abraxis trades on the Nasdaq National Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com. FORWARD-LOOKING STATEMENT forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the expected cost benefits and the acceleration of the market penetration for ABRAXANE as a result of the co-promotion agreement, global expansion, and the accretive effect of these transactions to earnings. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the continued market adoption and demand of ABRAXANE in North America and its potential market penetration outside of the U.S., the costs associated with the ongoing launch of ABRAXANE, the continued market acceptance of the new products acquired from AstraZeneca, AstraZeneca's ability to satisfy its obligations under the supply agreement, the difficulties or delays in developing, testing, obtaining regulatory approval of, and producing and marketing any other products, including those in the pipeline, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, the ability to successfully manufacture products in a time-sensitive and cost-effective manner, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in Abraxis BioScience's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2005 and other documents it has filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion